Pharmacokinetic investigation of oral itraconazole in stratum corneum level of tinea pedis

Mycoses

Volumn 47, Issue 3-4, 2004, Pages 104-114

  Morimoto, K ^a   Tanuma, H ^b   Kikuchi, I ^a   Kusunoki, T ^a   Kawana, S ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Tanuma Dermatology Clinic   (Japan)

Author keywords

Antimycotic chemotherapy; Itraconazole; Pharmacokinetics; Stratum corneum; Tinea pedis

Indexed keywords

HYDROXYITRACONAZOLE; ITRACONAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOPHYTE; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TISSUE LEVEL; FEMALE; FOOT SOLE; HUMAN; HYPERKERATOSIS; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SIDE EFFECT; STRATUM CORNEUM; TINEA PEDIS; TRICHOPHYTON RUBRUM;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; EPIDERMIS; FEMALE; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; TINEA PEDIS; TREATMENT OUTCOME;

ARTHRODERMATACEAE; TINEA; TRICHOPHYTON; TRICHOPHYTON RUBRUM;

EID: 2342489371     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1439-0507.2003.00952.x     Document Type: Article

References (27)

1. Cauwenberg G, Degreef H, Heykants J et al. Pharmacokinetics profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263-8.
2. Dermatology Study Group on Itraconazole. Clinical studies on a novel oral antifungal agent itraconazole against hyperkeratotic type tinea manuum, tinea pedis, tinea capitis, kerion celsi, and sycosis trichophytica. Clin Rep 1991; 25: 423-32.
3. Tanuma H, Nishiyama S. Clinical evaluation of bifonazole for moccasin-type tinea pedis. Mycoses 1997; 40: 223-8.
4. Tanuma H, Doi M, Yaguchi A et al. Efficacy of oral fluconazole in tinea pedis of the hyperkeratotic type. Stratum corneum levels. Mycoses 1998; 41: 153-62.
5. Tanuma H. Pathogenesis and treatment of hyperkeratotic tinea pedis in Japan. Mycoses 1999; 42: 21-28.
6. Tanuma H, Doi M, Ohta Y et al. Usefulness of 1% terbinafine HCI (Lamisil®) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. Mycoses 2000; 43: 417-32.
7. Tanuma H, Doi M, Sato N et al. Bifonazole (Mycospor® cream) in the treatment of moccasin-type tinea pedis. Comparison between combination therapy of bifonazole cream + 10% urea ointment (Urepearl®) and occlusive dressing therapy with the same agents. Mycoses 2000; 43: 129-37.
8. Umezawa A, Tanuma H, Omi M. Clinical use of tioconazole cream against hyperkeratotic type tinea pedis. Diagn New Drugs 1985; 22: 263-5.
9. Tanuma H, Nakamura K, Iwasaki M, Nishiyama S. Study on the clinical effectiveness of bifonazole (Mycospor® liquid) against hyperkeratotic type tinea pedis: comparison with a concomitant use of 10% urea ointment (Urepearl®). Nishi Nihon J Dermatol 1990; 51: 1207-10.
10. Tanuma H. Treatment of hyperkeratotic type tinea pedis. Jpn J Clin Dermatol 1995; 37: 1939-16.
11. Tanuma H, Doi M, Yaguchi A et al. Fluconazole oral administration: its usefulness against hyperkeratotic type tinea pedis and transfer into the corneum. Nishi Nihon J Dermatol 1996; 58: 668-75.
12. Ohta Y, Tanuma H, Katsuoka K. Treatment of hyperkeratotic type tinea pedis with single administration of butenafine hydrochloride (Mentax®) as compared to a concomitant use of urea ointment. Nishi Nihon J Dermatol 1996; 58: 1033-7.
13. Doncker P, Van Lint, Dockx P et al. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis 1995; 56: 180-3.
14. Doncker P, Decroix J, Pierard GE et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetics and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996; 132: 34-41.
15. Matsumoto T, Tanuma H, Nishiyama S. Clinical and pharmacokinetic studies on internal use of itraconazole for the treatment of onychomycosis. Nishi Nihon J Dermatol 1996; 58: 887-95.
16. Tanuma H. Current topics in diagnosis and treatment of tinea unguium in Japan. J Dermatol 1999; 26: 87-97.
17. Matsumoto T, Tanuma H, Nishiyama S. Clinical and pharmacokinetic investigation of oral itraconazole in the treatment of onychomycosis. Mycoses 1999; 42: 79-91.
18. Heykants J, Van Peer C, Van de velde V et al. Pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32 (Suppl. 1): 67-87.
19. Hooning PK, Wortham DC, Hull R. Itraconazole affects single-dose terfendadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993; 33: 1201-6.
20. Tanuma H. External and internal therapy for hyperkeratotic type tinea pedis. Jpn J Clin Dermatol 2001; 68: 138-13.
21. Tanuma H, Tanuma M, Doi M, Nakamura K, Katsuoka K, Abe M. Studies on usefulness of itraconazole short-term administration against treatment-resistant tinea pedis: difference between direct microscopy using potassium hydroxide preparation and cultivation. Proceedings of the 7th Dermatological Mycology Club Regular Meeting. Tokyo: Axel Springer Japan. 2001: 110-6.
22. Tanuma H, Doi M, Nakamura K. Usefulness of short-term administration of itraconazole as a treatment of hyperkeratotic type tinea pedis. Jpn J Clin Dermatol (2001); 55 (Special issue): S75-76.
23. Lavrijsen APM, Balmus KJ, Nugteren-Huying WM et al. Hepatic injury associated with itraconazole. Lancet 1992; 340: 251-2.
24. Hann SK, Kim JB, Im S et al. Itraconazole-induced acute hepatitis. Br J Dermatol 1993; 129: 500-1.
25. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. Am Acad Dermatol 1993; 29: 50-54.
26. Odds FC, Vanden Bossche H. Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. J Antimicrob Chemother 2000; 45: 371-3.
27. Uchida K, Hosaka J, Aoki K, Yamaguchi H. In vitro antifungal activity of itraconazole, a new triazole antifungal agent, against clinical isolates from patients with dermatomycoses. Jpn J Antibiot 1991; 44: 571-9.